{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:49:04Z","timestamp":1790938144417,"version":"4.1.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Cancer Center Research and Development Funds","award":["23-A-20,\u00a026-A-4"],"award-info":[{"award-number":["23-A-20,\u00a026-A-4"]}]},{"name":"National Cancer Center Research and Development Funds","award":["29-A-3"],"award-info":[{"award-number":["29-A-3"]}]},{"name":"National Cancer Center Research and Development Funds","award":["2020-J-3"],"award-info":[{"award-number":["2020-J-3"]}]},{"name":"National Cancer Center Research and Development Funds","award":["H26-088"],"award-info":[{"award-number":["H26-088"]}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare of Japan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["JP16ck0106091"],"award-info":[{"award-number":["JP16ck0106091"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["JP19ck0106341"],"award-info":[{"award-number":["JP19ck0106341"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JSPS KAKENHI","award":["20K09375"],"award-info":[{"award-number":["20K09375"]}]},{"name":"Merck Sharp & Dohme Corp"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The goal was to determine whether the addition of temozolomide (TMZ) to the standard treatment of high-dose methotrexate (HD-MTX) and whole-brain radiotherapy (WBRT) for primary central nervous system lymphoma (PCNSL) improves survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An open-label, randomized, phase III trial was conducted in Japan, enrolling immunocompetent patients aged 20\u201370 years with histologically confirmed, newly diagnosed PCNSL. After administration of HD-MTX, patients were randomly assigned to receive WBRT (30 Gy)\u2005\u00b1\u200510 Gy boost (arm A) or WBRT\u2005\u00b1\u2005boost with concomitant and maintenance TMZ for 2 years (arm B). The primary endpoint was overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between September 29, 2014 and October 15, 2018, 134 patients were enrolled, of whom 122 were randomly assigned and analyzed. At the planned interim analysis, 2-year OS was 86.8% (95% confidence interval [CI]: 72.5\u201394.0%) in arm A and 71.4% (56.0\u201382.2%) in arm B. The hazard ratio was 2.18 (95% CI: 0.95\u20134.98), with the predicted probability of showing the superiority of arm B at the final analysis estimated to be 1.3%. The study was terminated early due to futility. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status was measured in 115 tumors, and it was neither prognostic nor predictive of TMZ response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study failed to demonstrate the benefit of concomitant and maintenance TMZ in newly diagnosed PCNSL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noac246","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T09:07:46Z","timestamp":1667639266000},"page":"687-698","source":"Crossref","is-referenced-by-count":31,"title":["Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with\/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C"],"prefix":"10.1093","volume":"25","author":[{"given":"Kazuhiko","family":"Mishima","sequence":"first","affiliation":[{"name":"Department of Neuro-Oncology\/Neurosurgery, Saitama Medical University International Medical Center , Saitama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology\/Neurosurgery, Saitama Medical University International Medical Center , Saitama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4303-6006","authenticated-orcid":false,"given":"Yoshitaka","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8123-5298","authenticated-orcid":false,"given":"Junki","family":"Mizusawa","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minako","family":"Sumi","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Tokyo Metropolitan Geriatric Hospital , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology\/Neurosurgery, Saitama Medical University International Medical Center , Saitama , Japan"},{"name":"Department of Neurosurgery, Faculty of Medicine, The University of Tokyo , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyoshi","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kyorin University Faculty of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka International Cancer Institute , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0018-1652","authenticated-orcid":false,"given":"Motoo","family":"Nagane","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kyorin University Faculty of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4626-4645","authenticated-orcid":false,"given":"Yoshiki","family":"Arakawa","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kyoto University Graduate School of Medicine , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yoshimoto","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima University , Kagoshima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiyo","family":"Shibahara","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kitasato University School of Medicine , Sagamihara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Shinojima","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kumamoto University Graduate School of Medicine , Kumamoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Hirosaki University Graduate School of Medicine , Hirosaki, Japan"},{"name":"Department of Diagnostic Imaging and Nuclear Medicine, Tokyo Women\u2019s Medical University , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Tsurubuchi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine, University of Tsukuba , Tsukuba , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Keio University School of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Asai","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kansai Medical University , Hirakata , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sasayama","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kobe University Graduate School of Medicine , Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutomo","family":"Momii","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Oita University Faculty of Medicine , Oita , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical University , Saitama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nagoya University Hospital , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Anatomical and Surgical Pathology, Dokkyo University School of Medicine , Saitama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Tamaru","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University , Saitama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Department of Radiology, Saitama Medical Center, Saitama Medical University , Saitama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Gomyo","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kyorin University Faculty of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Hirosaki University Graduate School of Medicine , Hirosaki, Japan"},{"name":"Department of Diagnostic Imaging and Nuclear Medicine, Tokyo Women\u2019s Medical University , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3098-8323","authenticated-orcid":false,"given":"Manabu","family":"Natsumeda","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, University of Niigata , Niigata , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiyuki","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University , Hiroshima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9735-6630","authenticated-orcid":false,"given":"Hiroshi","family":"Katayama","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,5]]},"reference":[{"issue":"2","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11912-018-0666-1","article-title":"Updates on primary central nervous system lymphoma","volume":"20","author":"Schaff","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0360-3016(92)90538-S","article-title":"Non-Hodgkin\u2019s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315","volume":"23","author":"Nelson","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"3","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/JCO.2000.18.3.519","article-title":"Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma","volume":"18","author":"O\u2019Brien","year":"2000","journal-title":"J Clin Oncol."},{"issue":"11","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","article-title":"High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomized, non-inferiority trial","volume":"11","author":"Thiel","year":"2010","journal-title":"Lancet Oncol."},{"key":"2023040607123610800_","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noac196","article-title":"European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)","author":"Hoang-Xuan","year":"2023;25(1):37\u201353.","journal-title":"Neuro Oncol"},{"issue":"2","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1996.14.2.556","article-title":"Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06","volume":"14","author":"Schultz","year":"1996","journal-title":"J Clin Oncol."},{"issue":"24","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","article-title":"Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation Therapy Oncology Group Study 93-10","volume":"20","author":"DeAngelis","year":"2002","journal-title":"J Clin Oncol."},{"issue":"11","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1158\/1078-0432.CCR-03-0807","article-title":"Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients","volume":"10","author":"Ostermann","year":"2004","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1158\/1078-0432.CCR-07-1856","article-title":"In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide","volume":"14","author":"Kil","year":"2008","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"issue":"14","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1200\/JCO.2015.64.8634","article-title":"Phase I and II study of induction chemotherapy with methotrexate rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG Oncology RTOG 0227","volume":"34","author":"Glass","year":"2016","journal-title":"J Clin Oncol."},{"issue":"25","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGG 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J Clin Oncol."},{"issue":"6","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.bjc.6603660","article-title":"Temozolomide as salvage treatment in primary brain lymphomas","volume":"96","author":"Reni","year":"2007","journal-title":"Br J Cancer."},{"issue":"5","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.blre.2018.03.003","article-title":"The possible role of maintenance treatment for primary central nervous system lymphoma","volume":"34","author":"Bairey","year":"2018","journal-title":"Blood Rev."},{"issue":"2","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bjc.1992.57","article-title":"Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)","volume":"65","author":"Newlands","year":"1992","journal-title":"Br J Cancer."},{"issue":"19","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM200011093431901","article-title":"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents","volume":"343","author":"Esteller","year":"2000","journal-title":"N Engl J Med."},{"issue":"22","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol."},{"issue":"5","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00401-011-0803-5","article-title":"A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts","volume":"121","author":"Malley","year":"2011","journal-title":"Acta Neuropathol."},{"issue":"5","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/ijc.26499","article-title":"MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations","volume":"131","author":"Mulholland","year":"2012","journal-title":"Int J Cancer."},{"issue":"1","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1186\/s12885-021-08834-0","article-title":"A randomized phase III study of short-course radiotherapy combined with temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII)","volume":"21","author":"Arakawa","year":"2021","journal-title":"BMC Cancer."},{"issue":"10","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med."},{"issue":"6","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1158\/1078-0432.CCR-18-3181","article-title":"MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: a pooled analysis of four clinical trials","volume":"25","author":"Hegi","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"24","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1200\/JCO.2003.03.108","article-title":"High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962","volume":"21","author":"Poortmans","year":"2003","journal-title":"J Clin Oncol."},{"issue":"1","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2002.20.1.231","article-title":"Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD\/BVAM regimen followed by two different radiotherapy treatments","volume":"20","author":"Bessell","year":"2002","journal-title":"J Clin Oncol."},{"issue":"2","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijrobp.2005.07.958","article-title":"Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group)","volume":"64","author":"O\u2019Brien","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"32","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J Clin Oncol."},{"issue":"12","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/neuonc\/noaa107","article-title":"A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)","volume":"22","author":"Balana","year":"2020","journal-title":"Neuro Oncol."},{"issue":"15\u201316","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/sim.4780121516","article-title":"Applying Bayesian ideas in drug development and clinical trials","volume":"12","author":"Spiegelhalter","year":"1993","journal-title":"Stat Med."},{"issue":"36","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol."},{"issue":"6","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S2352-3026(15)00074-5","article-title":"Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial","volume":"2","author":"Omuro","year":"2015","journal-title":"Lancet Haematol."},{"issue":"4","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3324\/haematol.2014.108472","article-title":"Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group","volume":"100","author":"Pulczynski","year":"2015","journal-title":"Haematologica."},{"issue":"10","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.6004\/jnccn.2015.0151","article-title":"Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors","volume":"13","author":"Grossman","year":"2015","journal-title":"J Natl Compr Canc Netw."},{"issue":"10","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.3109\/10428194.2010.508825","article-title":"Lymphopenia a simple prognostic factor in lymphoma and other cancers: why not use it more as a guide?","volume":"51","author":"Tadmor","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejca.2016.01.016","article-title":"A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma","volume":"57","author":"Jang","year":"2016","journal-title":"Eur J Cancer."},{"issue":"1","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/jnci\/94.1.26","article-title":"Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma","volume":"94","author":"Esteller","year":"2002","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11060-011-0721-3","article-title":"O 6 -methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment","volume":"107","author":"Adachi","year":"2012","journal-title":"J Neurooncol"},{"issue":"2","key":"2023040607123610800_","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1158\/1078-0432.CCR-13-0669","article-title":"Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma","volume":"20","author":"Leshchenko","year":"2014","journal-title":"Clin Cancer Res"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noac246\/49118967\/noac246.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/25\/4\/687\/49775520\/noac246.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/25\/4\/687\/49775520\/noac246.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T22:53:17Z","timestamp":1701298397000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/25\/4\/687\/6805594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,5]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,11,5]]},"published-print":{"date-parts":[[2023,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noac246","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2022,11,5]]}}}